{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:23Z","timestamp":1793397923932,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11154-026-10039-4","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:12:01Z","timestamp":1776409921000},"page":"781-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy for aggressive pituitary tumors and carcinomas"],"prefix":"10.1007","volume":"27","author":[{"given":"Mirela-Diana","family":"Ilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lamback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"10039_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvaf100","volume":"192","author":"G Raverot","year":"2025","unstructured":"Raverot G, Burman P, Abreu AP, Heaney AP, Van Hulsteijn L, Lin AL, et al. Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas. Eur J Endocrinol. 2025;192:G1-34. https:\/\/doi.org\/10.1093\/ejendo\/lvaf100.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0021","volume":"30","author":"C Villa","year":"2023","unstructured":"Villa C, Baussart B, Assi\u00e9 G, Raverot G, Roncaroli F. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer. 2023;30:e230021. https:\/\/doi.org\/10.1530\/ERC-23-0021.","journal-title":"Endocr Relat Cancer"},{"key":"10039_CR3","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0338","volume":"30","author":"P Raymond","year":"2023","unstructured":"Raymond P, Raverot G, Ilie M-D. Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review. Endocr Relat Cancer. 2023;30:e220338. https:\/\/doi.org\/10.1530\/ERC-22-0338.","journal-title":"Endocr Relat Cancer"},{"key":"10039_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022;187:593\u2013605. https:\/\/doi.org\/10.1530\/EJE-22-0440.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR5","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1093\/ejendo\/lvad042","volume":"188","author":"J Trouillas","year":"2023","unstructured":"Trouillas J, Burman P, Losa M, McCormack A, Petersenn S, Popovic V, et al. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?\u2014that is the question. Eur J Endocrinol. 2023;188:C1-5. https:\/\/doi.org\/10.1093\/ejendo\/lvad042.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17:671\u201384. https:\/\/doi.org\/10.1038\/s41574-021-00550-w.","journal-title":"Nat Rev Endocrinol"},{"key":"10039_CR7","doi-asserted-by":"publisher","first-page":"e1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstr\u00f6m BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. J Clin Endocrinol Metab. 2021;106:e1183-94. https:\/\/doi.org\/10.1210\/clinem\/dgaa749.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","volume":"189","author":"J Simon","year":"2023","unstructured":"Simon J, Perez-Rivas LG, Zhao Y, Chasseloup F, Lasolle H, Cortet C, et al. Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours. Eur J Endocrinol. 2023;189:372\u20138. https:\/\/doi.org\/10.1093\/ejendo\/lvad114.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02736-8","volume":"147","author":"AL Lin","year":"2024","unstructured":"Lin AL, Rudneva VA, Richards AL, Zhang Y, Woo HJ, Cohen M, et al. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathol (Berl). 2024;147:85. https:\/\/doi.org\/10.1007\/s00401-024-02736-8.","journal-title":"Acta Neuropathol (Berl)"},{"key":"10039_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108506","volume":"250","author":"M-D Ilie","year":"2023","unstructured":"Ilie M-D, De Alcubierre D, Carretti AL, Jouanneau E, Raverot G. Therapeutic targeting of the pituitary tumor microenvironment. Pharmacol Ther. 2023;250:108506. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108506.","journal-title":"Pharmacol Ther"},{"key":"10039_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.23736\/S2724-6507.23.04058-7","volume":"49","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D, Carretti AL, Ducray F, Jouanneau E, Raverot G, Ilie MD. Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide. Minerva Endocrinol. 2024;49:321\u201334. https:\/\/doi.org\/10.23736\/S2724-6507.23.04058-7.","journal-title":"Minerva Endocrinol"},{"key":"10039_CR12","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1-24. https:\/\/doi.org\/10.1530\/EJE-17-0796.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J Clin Endocrinol Metab. 2023;108:1585\u2013601. https:\/\/doi.org\/10.1210\/clinem\/dgad098.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.700007","volume":"12","author":"M Luo","year":"2021","unstructured":"Luo M, Tan Y, Chen W, Hu B, Wang Z, Zhu D, et al. Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis. Front Neurol. 2021;12:700007. https:\/\/doi.org\/10.3389\/fneur.2021.700007.","journal-title":"Front Neurol"},{"key":"10039_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178:265\u201376. https:\/\/doi.org\/10.1530\/EJE-17-0933.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide. J Clin Endocrinol Metab. 2015;100:1689\u201398. https:\/\/doi.org\/10.1210\/jc.2014-4350.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-020-03579-5","volume":"149","author":"G Minniti","year":"2020","unstructured":"Minniti G, Paolini S, Rea MLJ, Isidori A, Scaringi C, Russo I, et al. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas. J Neurooncol. 2020;149:123\u201330. https:\/\/doi.org\/10.1007\/s11060-020-03579-5.","journal-title":"J Neurooncol"},{"key":"10039_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, et al. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab. 2013;98:1130\u20136. https:\/\/doi.org\/10.1210\/jc.2012-2924.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1437436","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Jia P, Fang Y, Zhu W, Gong Y, Fan T, et al. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database. Front Pharmacol. 2024;15:1437436. https:\/\/doi.org\/10.3389\/fphar.2024.1437436.","journal-title":"Front Pharmacol"},{"key":"10039_CR20","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","volume":"23","author":"Y Yu","year":"2021","unstructured":"Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH -mutant gliomas. Neuro-Oncology. 2021;23:1872\u201384. https:\/\/doi.org\/10.1093\/neuonc\/noab081.","journal-title":"Neuro-Oncology"},{"key":"10039_CR21","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1210\/clinem\/dgaf178","volume":"110","author":"AL Lin","year":"2025","unstructured":"Lin AL, Rudneva V, Newton A, Majd NK, Magge R, Sengupta S, et al. Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumors. J Clin Endocrinol Metab. 2025;110:3066\u201373. https:\/\/doi.org\/10.1210\/clinem\/dgaf178.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR22","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. 2018;103:3925\u201330. https:\/\/doi.org\/10.1210\/jc.2018-01347.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1210\/clinem\/dgae615","volume":"110","author":"T Paes","year":"2025","unstructured":"Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz CP, et al. Somatic activating ESR1 mutation in an aggressive prolactinoma. J Clin Endocrinol Metab. 2025;110:1166\u201376. https:\/\/doi.org\/10.1210\/clinem\/dgae615.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y.","journal-title":"Nat Commun"},{"key":"10039_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Villa C, Cuny T, Cortet C, Assie G, Baussart B, et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur J Endocrinol. 2022;187:685\u201396. https:\/\/doi.org\/10.1530\/EJE-22-0647.","journal-title":"Eur J Endocrinol"},{"key":"10039_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001532","volume":"8","author":"N Majd","year":"2020","unstructured":"Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020;8:e001532. https:\/\/doi.org\/10.1136\/jitc-2020-001532.","journal-title":"J Immunother Cancer"},{"key":"10039_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab133","volume":"5","author":"AL Lin","year":"2021","unstructured":"Lin AL, Tabar V, Young RJ, Cohen M, Cuaron J, Yang TJ, et al. Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma. J Endocr Soc. 2021;5:bvab133. https:\/\/doi.org\/10.1210\/jendso\/bvab133.","journal-title":"J Endocr Soc"},{"key":"10039_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","volume":"31","author":"M Caccese","year":"2020","unstructured":"Caccese M, Barbot M, Ceccato F, Padovan M, Gardiman MP, Fassan M, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs. 2020;31:199\u2013204. https:\/\/doi.org\/10.1097\/CAD.0000000000000856.","journal-title":"Anticancer Drugs"},{"key":"10039_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.576027","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim H-W, McCormack AI. Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy. Front Endocrinol. 2020. https:\/\/doi.org\/10.3389\/fendo.2020.576027.","journal-title":"Front Endocrinol"},{"key":"10039_CR30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0151","author":"B Sol","year":"2020","unstructured":"Sol B, de Filette JMk, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu Ce, et al. Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: a new emerging treatment? Eur J Endocrinol [Internet]. 2020. https:\/\/doi.org\/10.1530\/EJE-20-0151. [cited 2020 Oct 31].","journal-title":"Eur J Endocrinol [Internet]"},{"key":"10039_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174093","volume":"14","author":"T Feola","year":"2022","unstructured":"Feola T, Carbonara F, Verrico M, Di Crescenzo RM, Gianno F, Colonnese C, et al. Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): state-of-the art. Cancers. 2022;14:4093. https:\/\/doi.org\/10.3390\/cancers14174093.","journal-title":"Cancers"},{"key":"10039_CR32","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","volume":"91","author":"S Shah","year":"2022","unstructured":"Shah S, Manzoor S, Rothman Y, Hagen M, Pater L, Golnik K, et al. Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report. Neurosurgery. 2022;91:e51-6. https:\/\/doi.org\/10.1227\/neu.0000000000002024.","journal-title":"Neurosurgery"},{"key":"10039_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/endrev\/bnac024","volume":"44","author":"M-D Ilie","year":"2023","unstructured":"Ilie M-D, Vasiljevic A, Bertolino P, Raverot G. Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas. Endocr Rev. 2023;44:297\u2013311. https:\/\/doi.org\/10.1210\/endrev\/bnac024.","journal-title":"Endocr Rev"},{"issue":"1","key":"10039_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf241","volume":"28","author":"M-D Ilie","year":"2025","unstructured":"Ilie M-D, Flores-Mart\u00ednez \u00c1, Chanal M, Lepetit M, Samson B, Lehiani A, et al. Mast cells act as pro-angiogenic and pro-tumorigenic players in pituitary gonadotroph tumors. Neuro-oncol. 2025;noaf241. https:\/\/doi.org\/10.1093\/neuonc\/noaf241.","journal-title":"Neuro-oncol"},{"key":"10039_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290:6\u201323. https:\/\/doi.org\/10.1111\/imr.12766.","journal-title":"Immunol Rev"},{"key":"10039_CR36","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","volume":"25","author":"OE Rahma","year":"2019","unstructured":"Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25:5449\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1543.","journal-title":"Clin Cancer Res"},{"key":"10039_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci. 2017;41:75\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052.","journal-title":"J Clin Neurosci"},{"key":"10039_CR38","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1210\/jc.2019-00432","volume":"104","author":"P Dutta","year":"2019","unstructured":"Dutta P, Reddy KS, Rai A, Madugundu AK, Solanki HS, Bhansali A, et al. Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation\u2012positive child. J Clin Endocrinol Metab. 2019;104:3539\u201344. https:\/\/doi.org\/10.1210\/jc.2019-00432.","journal-title":"J Clin Endocrinol Metab"},{"key":"10039_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","volume":"122","author":"LE Rotman","year":"2019","unstructured":"Rotman LE, Vaughan TB, Hackney JR, Riley KO. Long-term survival after transformation of an adrenocorticotropic hormone\u2013secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma. World Neurosurg. 2019;122:417\u201323. https:\/\/doi.org\/10.1016\/j.wneu.2018.11.011.","journal-title":"World Neurosurg"},{"key":"10039_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","volume":"15","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, et al. Anti-VEGF therapy in pituitary carcinoma. Pituitary. 2012;15:445\u20139. https:\/\/doi.org\/10.1007\/s11102-011-0346-8.","journal-title":"Pituitary"},{"key":"10039_CR41","doi-asserted-by":"publisher","first-page":"e13022","DOI":"10.1200\/jco.2013.31.15_suppl.e13022","volume":"31","author":"LM O\u2019Riordan","year":"2013","unstructured":"O\u2019Riordan LM, Greally M, Coleman N, Breathnach OS, Hennessy B, Thompson CJ, et al. Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: a case report. J Clin Oncol. 2013;31:e13022\u2013e13022. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.e13022.","journal-title":"J Clin Oncol"},{"key":"10039_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/623092","volume":"2015","author":"M Kurowska","year":"2015","unstructured":"Kurowska M, Nowakowski A, Zieli\u0144ski G, Malicka J, Tarach JS, Maksymowicz M, et al. Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with Nelson\u2019s syndrome: a case report and review of the literature. Case Rep Endocrinol. 2015;2015:1\u20138. https:\/\/doi.org\/10.1155\/2015\/623092.","journal-title":"Case Rep Endocrinol"},{"key":"10039_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","volume":"30","author":"OM Alshaikh","year":"2019","unstructured":"Alshaikh OM, Asa SL, Mete O, Ezzat S. An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors. Endocr Pathol. 2019;30:118\u201327. https:\/\/doi.org\/10.1007\/s12022-019-9568-5.","journal-title":"Endocr Pathol"},{"key":"10039_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030088","volume":"10","author":"C Duhamel","year":"2020","unstructured":"Duhamel C, Ilie MD, Salle H, Nassouri AS, Gaillard S, Deluche E, et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature. J Pers Med. 2020;10:88. https:\/\/doi.org\/10.3390\/jpm10030088.","journal-title":"J Pers Med"},{"key":"10039_CR45","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/a-1260-3975","volume":"129","author":"K Osterhage","year":"2021","unstructured":"Osterhage K, Rotermund R, Droste M, Dierlamm J, Saeger W, Petersenn S, et al. Bevacizumab in aggressive pituitary adenomas \u2013 experience with 3 patients. Exp Clin Endocrinol Diabetes. 2021;129:178\u201385. https:\/\/doi.org\/10.1055\/a-1260-3975.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10039_CR46","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","volume":"11","author":"AM Jubb","year":"2010","unstructured":"Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11:1172\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(10)70232-1.","journal-title":"Lancet Oncol"},{"key":"10039_CR47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","volume":"31","author":"D Lambrechts","year":"2013","unstructured":"Lambrechts D, Lenz H-J, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219\u201330. https:\/\/doi.org\/10.1200\/JCO.2012.46.2762.","journal-title":"J Clin Oncol"},{"key":"10039_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81914-0","volume":"11","author":"K Kr\u00fcger","year":"2021","unstructured":"Kr\u00fcger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, et al. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Sci Rep. 2021;11:3388. https:\/\/doi.org\/10.1038\/s41598-021-81914-0.","journal-title":"Sci Rep"},{"key":"10039_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JTO.0b013e31823085f4","volume":"7","author":"Y-Y Zhao","year":"2012","unstructured":"Zhao Y-Y, Xue C, Jiang W, Zhao H-Y, Huang Y, Feenstra K, et al. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. J Thorac Oncol. 2012;7:71\u20135. https:\/\/doi.org\/10.1097\/JTO.0b013e31823085f4.","journal-title":"J Thorac Oncol"},{"key":"10039_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102710","volume":"15","author":"P Marques","year":"2023","unstructured":"Marques P. The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary. Cancers. 2023;15:2710. https:\/\/doi.org\/10.3390\/cancers15102710.","journal-title":"Cancers"},{"key":"10039_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/eci.12010","volume":"43","author":"GL Kov\u00e1cs","year":"2013","unstructured":"Kov\u00e1cs GL, G\u00f3th M, Rotondo F, Scheithauer BW, Carlsen E, Saadia A, et al. ACTH-secreting Crooke cell carcinoma of the pituitary: CROOKE CELL CARCINOMA OF THE PITUITARY. Eur J Clin Invest. 2013;43:20\u20136. https:\/\/doi.org\/10.1111\/eci.12010.","journal-title":"Eur J Clin Invest"},{"key":"10039_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","volume":"17","author":"J Komor","year":"2014","unstructured":"Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. 2014;17:227\u201331. https:\/\/doi.org\/10.1007\/s11102-013-0494-0.","journal-title":"Pituitary"},{"key":"10039_CR53","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","volume":"17","author":"J Maclean","year":"2014","unstructured":"Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17:530\u20138. https:\/\/doi.org\/10.1007\/s11102-013-0540-y.","journal-title":"Pituitary"},{"key":"10039_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","volume":"40","author":"F Novruzov","year":"2015","unstructured":"Novruzov F, Aliyev JA, Jaunmuktane Z, Bomanji JB, Kayani I. The use of 68Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of 177Lu DOTATATE therapy in pituitary carcinoma. Clin Nucl Med. 2015;40:47\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000000589.","journal-title":"Clin Nucl Med"},{"key":"10039_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","volume":"125","author":"J Walig\u00f3rska-Stachura","year":"2016","unstructured":"Walig\u00f3rska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczy\u0144ska M, Baszko-B\u0142aszyk D, et al. Growth hormone\u2013secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report. J Neurosurg. 2016;125:346\u20139. https:\/\/doi.org\/10.3171\/2015.6.JNS15363.","journal-title":"J Neurosurg"},{"key":"10039_CR56","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","volume":"47","author":"M Assadi","year":"2020","unstructured":"Assadi M, Nemati R, Shooli H, Rekabpour SJ, Nabipour I, Jafari E, et al. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020;47:1015\u20136. https:\/\/doi.org\/10.1007\/s00259-019-04578-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10039_CR57","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/EC-19-0065","volume":"8","author":"G Giuffrida","year":"2019","unstructured":"Giuffrida G, Ferra\u00f9 F, Laudicella R, Cotta OR, Messina E, Granata F, et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocr Connect. 2019;8:528\u201335. https:\/\/doi.org\/10.1530\/EC-19-0065.","journal-title":"Endocr Connect"},{"key":"10039_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11102-011-0373-5","volume":"15","author":"S Baldari","year":"2012","unstructured":"Baldari S, Ferra\u00f9 F, Alafaci C, Herberg A, Granata F, Militano V, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. 2012;15:57\u201360. https:\/\/doi.org\/10.1007\/s11102-011-0373-5.","journal-title":"Pituitary"},{"key":"10039_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.wneu.2016.09.092","volume":"97","author":"SM Priola","year":"2017","unstructured":"Priola SM, Esposito F, Cannav\u00f2 S, Conti A, Abbritti RV, Barresi V, et al. Aggressive pituitary adenomas: the dark side of the moon. World Neurosurg. 2017;97:140\u201355. https:\/\/doi.org\/10.1016\/j.wneu.2016.09.092.","journal-title":"World Neurosurg"},{"key":"10039_CR60","doi-asserted-by":"publisher","DOI":"10.1530\/EO-25-0073","volume":"5","author":"KI Wolf","year":"2025","unstructured":"Wolf KI, Lu Z, Hesseltine EA, Wong K-K, Worden FP, Else T. Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor. Endocr Oncol. 2025;5:e250073. https:\/\/doi.org\/10.1530\/EO-25-0073.","journal-title":"Endocr Oncol"},{"key":"10039_CR61","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae123","volume":"2","author":"C Gandhi","year":"2024","unstructured":"Gandhi C, Koumna S, Chik C. Treatment of an aggressive gonadotroph pituitary neuroendocrine tumor with 177Lutetium DOTATATE radionuclide therapy. JCEM Case Reports. 2024;2:luae123. https:\/\/doi.org\/10.1210\/jcemcr\/luae123.","journal-title":"JCEM Case Reports"},{"key":"10039_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well\u2010differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36:e13423. https:\/\/doi.org\/10.1111\/jne.13423.","journal-title":"J Neuroendocrinol"},{"key":"10039_CR63","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2967\/jnumed.115.165092","volume":"57","author":"VF Taelman","year":"2016","unstructured":"Taelman VF, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu CI, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805\u201310. https:\/\/doi.org\/10.2967\/jnumed.115.165092.","journal-title":"J Nucl Med"},{"key":"10039_CR64","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58:61S-66S. https:\/\/doi.org\/10.2967\/jnumed.116.186783.","journal-title":"J Nucl Med"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10039-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:29:13Z","timestamp":1784608153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10039-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10039"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10039-4","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}